# SS Innovations International, Inc.: financial statements, quarterly

SSII · Nasdaq · CIK 1676163 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ssii.md) · [Financials](/companies/ssii/financials.md) · [Filings](/companies/ssii/filings.md) · [Insiders](/companies/ssii/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ssii/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2.2](/filings/0001213900-25-026691.md) | [1.4 d](/filings/0001213900-24-110779.md) | [3.6](/filings/0001213900-25-043327.md) | [4.5](/filings/0001213900-25-072563.md) | [4.4](/filings/0001213900-25-103135.md) | [8.1 d](/filings/0001213900-26-025440.md) | [5.1](/filings/0001213900-26-055403.md) | [10.0](/filings/0001213900-25-072563.md) | [12.8](/filings/0001213900-25-103135.md) | [14.5 d](/filings/0001213900-26-025440.md) | [11.1](/filings/0001213900-26-055403.md) | [13.9](/filings/0001213900-26-088721.md) |
| Cost of revenue | $m | [1.9](/filings/0001213900-25-026691.md) | [1.8 d](/filings/0001213900-25-031773.md) | [2.9](/filings/0001213900-25-043327.md) | [3.1](/filings/0001213900-25-072563.md) | [2.1](/filings/0001213900-25-103135.md) | [4.1 d](/filings/0001213900-26-025440.md) | [4.0](/filings/0001213900-26-055403.md) | [4.1](/filings/0001213900-26-088721.md) | [6.7](/filings/0001213900-25-103135.md) | [8.2 d](/filings/0001213900-26-025440.md) | [5.8](/filings/0001213900-26-055403.md) | [6.8](/filings/0001213900-26-088721.md) |
| Gross profit | $m | [0.3](/filings/0001213900-25-026691.md) | [(0.4) d](/filings/0001213900-25-031773.md) | [0.7](/filings/0001213900-25-043327.md) | [1.4](/filings/0001213900-25-072563.md) | [2.3](/filings/0001213900-25-103135.md) | [4.0 d](/filings/0001213900-26-025440.md) | [1.1](/filings/0001213900-26-055403.md) | [5.9](/filings/0001213900-26-088721.md) | [6.2](/filings/0001213900-25-103135.md) | [6.4 d](/filings/0001213900-26-025440.md) | [5.3](/filings/0001213900-26-055403.md) | [7.1](/filings/0001213900-26-088721.md) |
| Research and development | $m | [0.3](/filings/0001213900-25-026691.md) | [0.3 d](/filings/0001213900-25-031773.md) | [0.5](/filings/0001213900-25-043327.md) | [0.8](/filings/0001213900-25-072563.md) | [0.4](/filings/0001213900-25-103135.md) | [0.8 d](/filings/0001213900-26-025440.md) | [1.0](/filings/0001213900-26-055403.md) | [0.5](/filings/0001213900-26-088721.md) | [0.8](/filings/0001213900-25-103135.md) | [1.4 d](/filings/0001213900-26-025440.md) | [1.0](/filings/0001213900-26-055403.md) | [2.4](/filings/0001213900-26-088721.md) |
| Selling, general and administrative | $m | [1.8](/filings/0001213900-25-026691.md) | [1.7 d](/filings/0001213900-25-031773.md) | [2.8](/filings/0001213900-25-043327.md) | [2.2](/filings/0001213900-25-072563.md) | [2.5](/filings/0001213900-25-103135.md) | [2.6 d](/filings/0001213900-26-025440.md) | [3.4](/filings/0001213900-26-055403.md) | [3.4](/filings/0001213900-26-088721.md) | [4.8](/filings/0001213900-25-103135.md) | [3.4 d](/filings/0001213900-26-025440.md) | [4.5](/filings/0001213900-26-055403.md) | [4.5](/filings/0001213900-26-088721.md) |
| Operating income | $m | [(1.9)](/filings/0001213900-25-026691.md) | [(12.2) d](/filings/0001213900-25-031773.md) | [(9.8)](/filings/0001213900-25-043327.md) | [(4.1)](/filings/0001213900-25-072563.md) | [(3.2)](/filings/0001213900-25-103135.md) | [(1.8) d](/filings/0001213900-26-025440.md) | [(5.9)](/filings/0001213900-26-055403.md) | [0.1](/filings/0001213900-26-088721.md) | [(1.8)](/filings/0001213900-25-103135.md) | [(0.7) d](/filings/0001213900-26-025440.md) | [(3.6)](/filings/0001213900-26-055403.md) | [(2.3)](/filings/0001213900-26-088721.md) |
| Interest expense | $m | [0.1](/filings/0001213900-25-026691.md) | [0.5 d](/filings/0001213900-24-025140.md) | [0.2](/filings/0001213900-24-043430.md) | [0.2](/filings/0001213900-25-072563.md) | [0.2](/filings/0001213900-25-103135.md) | [0.3 d](/filings/0001213900-26-025440.md) | [0.4](/filings/0001213900-26-055403.md) | [0.2](/filings/0001213900-26-088721.md) | [0.2](/filings/0001213900-25-103135.md) | [0.3 d](/filings/0001213900-26-025440.md) | [0.3](/filings/0001213900-26-055403.md) | [0.3](/filings/0001213900-26-088721.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.4](/filings/0001213900-26-088721.md) | [1.8](/filings/0001213900-25-103135.md) | [1.8 d](/filings/0001213900-26-025440.md) | [0.2](/filings/0001213900-26-055403.md) | [0.5](/filings/0001213900-26-088721.md) |
| Net income | $m | [(1.9)](/filings/0001213900-25-026691.md) | [(12.1) d](/filings/0001213900-25-031773.md) | [(9.8)](/filings/0001213900-25-043327.md) | [(4.1)](/filings/0001213900-25-072563.md) | [(3.2)](/filings/0001213900-25-103135.md) | [(1.9) d](/filings/0001213900-26-025440.md) | [(5.7)](/filings/0001213900-26-055403.md) | [(0.3)](/filings/0001213900-26-088721.md) | [(3.7)](/filings/0001213900-25-103135.md) | [(2.5) d](/filings/0001213900-26-025440.md) | [(3.6)](/filings/0001213900-26-055403.md) | [(2.7)](/filings/0001213900-26-088721.md) |
| Diluted EPS | $ per share | [(0.01)](/filings/0001213900-25-026691.md) | not reported | [(0.06)](/filings/0001213900-25-043327.md) | [(0.02)](/filings/0001213900-25-072563.md) | [(0.02)](/filings/0001213900-25-103135.md) | not reported | [(0.03)](/filings/0001213900-26-055403.md) | [0.00](/filings/0001213900-26-088721.md) | [(0.02)](/filings/0001213900-25-103135.md) | not reported | [(0.02)](/filings/0001213900-26-055403.md) | [(0.01)](/filings/0001213900-26-088721.md) |
| Basic EPS | $ per share | [(0.01)](/filings/0001213900-25-026691.md) | not reported | [(0.06)](/filings/0001213900-25-043327.md) | [(0.02)](/filings/0001213900-25-072563.md) | [(0.02)](/filings/0001213900-25-103135.md) | not reported | [(0.03)](/filings/0001213900-26-055403.md) | [0.00](/filings/0001213900-26-088721.md) | [(0.02)](/filings/0001213900-25-103135.md) | not reported | [(0.02)](/filings/0001213900-26-055403.md) | [(0.01)](/filings/0001213900-26-088721.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating, us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [6.6](/filings/0001213900-25-003409.md) | [2.0](/filings/0001213900-25-031773.md) | [0.9](/filings/0001213900-25-015053.md) | [0.6](/filings/0001213900-25-021899.md) | [0.2](/filings/0001213900-25-026691.md) | [0.5](/filings/0001213900-26-025440.md) | [15.9](/filings/0001213900-25-043327.md) | [11.4](/filings/0001213900-25-072563.md) | [5.7](/filings/0001213900-25-103135.md) | [3.2](/filings/0001213900-26-088721.md) | [16.0](/filings/0001213900-26-055403.md) | [13.6](/filings/0001213900-26-088721.md) |
| Current assets | $m | [22.7](/filings/0001213900-25-003409.md) | [21.4](/filings/0001213900-25-031773.md) | [23.6](/filings/0001213900-25-015053.md) | [23.3](/filings/0001213900-25-021899.md) | [25.1](/filings/0001213900-25-026691.md) | [27.4](/filings/0001213900-26-025440.md) | [47.6](/filings/0001213900-25-043327.md) | [50.8](/filings/0001213900-25-072563.md) | [48.4](/filings/0001213900-25-103135.md) | [48.8](/filings/0001213900-26-088721.md) | [66.3](/filings/0001213900-26-055403.md) | [71.5](/filings/0001213900-26-088721.md) |
| Total assets | $m | [28.2](/filings/0001213900-25-003409.md) | [31.5](/filings/0001213900-25-031773.md) | [35.2](/filings/0001213900-25-015053.md) | [35.7](/filings/0001213900-25-021899.md) | [39.0](/filings/0001213900-25-026691.md) | [42.4](/filings/0001213900-26-025440.md) | [63.5](/filings/0001213900-25-043327.md) | [70.0](/filings/0001213900-25-072563.md) | [69.6](/filings/0001213900-25-103135.md) | [74.2](/filings/0001213900-26-088721.md) | [90.5](/filings/0001213900-26-055403.md) | [97.0](/filings/0001213900-26-088721.md) |
| Current liabilities | $m | [8.5](/filings/0001213900-25-003409.md) | [8.5](/filings/0001213900-25-031773.md) | [13.0](/filings/0001213900-25-015053.md) | [15.0](/filings/0001213900-25-021899.md) | [18.5](/filings/0001213900-25-026691.md) | [21.3](/filings/0001213900-26-025440.md) | [15.0](/filings/0001213900-25-043327.md) | [19.6](/filings/0001213900-25-072563.md) | [21.2](/filings/0001213900-25-103135.md) | [26.2](/filings/0001213900-26-088721.md) | [26.0](/filings/0001213900-26-055403.md) | [31.9](/filings/0001213900-26-088721.md) |
| Total liabilities | $m | [11.8](/filings/0001213900-25-003409.md) | [11.8](/filings/0001213900-25-031773.md) | [18.5](/filings/0001213900-25-015053.md) | [20.9](/filings/0001213900-25-021899.md) | [25.3](/filings/0001213900-25-026691.md) | [28.9](/filings/0001213900-26-025440.md) | [22.9](/filings/0001213900-25-043327.md) | [28.0](/filings/0001213900-25-072563.md) | [29.9](/filings/0001213900-25-103135.md) | [36.0](/filings/0001213900-26-088721.md) | [36.0](/filings/0001213900-26-055403.md) | [43.6](/filings/0001213900-26-088721.md) |
| Long-term debt | $m | [0.5](/filings/0001213900-25-003409.md) | [0.5](/filings/0001213900-24-110779.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | [0.5](/filings/0001213900-25-003409.md) | [0.5](/filings/0001213900-25-031773.md) | [0.5](/filings/0001213900-25-015053.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [16.4](/filings/0001213900-25-026691.md) | [19.7](/filings/0001213900-26-025440.md) | [16.7](/filings/0001213900-25-103135.md) | [14.8](/filings/0001213900-25-103135.md) | [13.7](/filings/0001213900-25-103135.md) | [13.5](/filings/0001213900-26-088721.md) | [40.6](/filings/0001213900-26-088721.md) | [42.0](/filings/0001213900-26-088721.md) | [39.6](/filings/0001213900-25-103135.md) | [38.2](/filings/0001213900-26-088721.md) | [54.5](/filings/0001213900-26-088721.md) | [53.4](/filings/0001213900-26-088721.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(5,591) d](/filings/0001213900-25-026691.md) | [(4,394) d](/filings/0001213900-25-031773.md) | [(2,672)](/filings/0001213900-25-043327.md) | [(1,023) d](/filings/0001213900-25-072563.md) | [(2,547) d](/filings/0001213900-25-103135.md) | [(3,262) d](/filings/0001213900-26-025440.md) | [(6,103)](/filings/0001213900-26-055403.md) | [(3,452) d](/filings/0001213900-26-088721.md) | [(7,468) d](/filings/0001213900-25-103135.md) | [(1,520) d](/filings/0001213900-26-025440.md) | [(2,312)](/filings/0001213900-26-055403.md) | [(4,235) d](/filings/0001213900-26-088721.md) |
| Capital expenditure | $k | [221 d](/filings/0001213900-25-026691.md) | [127 d](/filings/0001213900-25-031773.md) | [127](/filings/0001213900-25-043327.md) | [2,112 d](/filings/0001213900-25-072563.md) | [(1,703) d](/filings/0001213900-25-103135.md) | [125 d](/filings/0001213900-26-025440.md) | [873](/filings/0001213900-26-055403.md) | [317 d](/filings/0001213900-25-072563.md) | [755 d](/filings/0001213900-25-103135.md) | [1,715 d](/filings/0001213900-26-025440.md) | [54.2](/filings/0001213900-26-055403.md) | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [128](/filings/0001213900-25-003409.md) | [128](/filings/0001213900-25-015053.md) | [144](/filings/0001213900-25-021899.md) | [148](/filings/0001213900-25-026691.md) | [182](/filings/0001213900-25-043327.md) | [182](/filings/0001213900-25-072563.md) | [182](/filings/0001213900-25-103135.md) | [189](/filings/0001213900-26-055403.md) | [203](/filings/0001213900-26-088721.md) | [203](/filings/0001213900-25-103135.md) | [205](/filings/0001213900-26-055403.md) | [209](/filings/0001213900-26-088721.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 200,385,435 at 2026-08-12, from the cover of the [10-Q filed 2026-08-13](/filings/0001213900-26-088721.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.